HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oncology
RCT
Phase II RCT finds no benefit for adding capecitabine to 177Lu-Dotatate in advanced NETs
Adding a Drug Actually Hurted These Patients
A Phase II randomized controlled trial in 111 patients with advanced somatostatin receptor-positive GEP or bronchopulmonary NETs compared…
Adding a common chemotherapy drug to cancer treatment actually made tumors grow faster and reduced survival time for these patients.
Apr 16, 2026
Oncology
RCT
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy
New Shot Cuts Severe Low White Blood Cell Risk
This prospective, single-center, open-label, exploratory, non-randomized controlled study evaluated subcutaneous PEG-rhG-CSF in 43 gastroint…
A simple shot given before chemotherapy could keep your body's infection-fighting cells strong when taking oral cancer pills.
Frontiers
Apr 16, 2026
Oncology
RCT
Neoadjuvant CAPOX chemotherapy alone showed comparable survival to chemoradiotherapy in locally advanced rectal cancer with uninvolved mesorectal fascia
Some Rectal Cancer Patients May Skip Radiation Without Losing Ground
This Phase III RCT compared 4 cycles of CAPOX chemotherapy alone versus chemoradiotherapy in patients with locally advanced rectal cancer an…
Some rectal cancer patients can skip pre-surgery radiation and still achieve similar cure rates while avoiding long-term side effects like b…
Apr 13, 2026
Oncology
Phase II
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer
Combination therapy shows promise for preventing biliary tract cancer recurrence after surgery
A single-arm phase II trial in 28 patients with resected biliary tract cancer at high risk of recurrence found median disease-free survival …
A new three-drug combination helped 68% of high-risk biliary tract cancer patients stay cancer-free for a year after surgery, with 91% still…
Apr 2, 2026
Gastroenterology
Phase II
Phase 2 trial tests metformin with neoadjuvant radiochemotherapy for locally advanced rectal cancer
Could a common diabetes drug help people with rectal cancer respond better to treatment?
A Phase 2 trial (n=60) evaluated adding metformin to neoadjuvant radiochemotherapy (capecitabine + 50 Gy radiation) for locally advanced rec…
Adding a common diabetes pill to pre-surgery treatment for rectal cancer may help clear out cancer cells before the operation begins.
CT.gov
Mar 30, 2026